Detection of γ-hydroxybutyrate in striatal microdialysates following peripheral 1,4-butanediol administration in rats

    loading  Checking for direct PDF access through Ovid

Abstract

The illicit use and abuse of 1,4-butanediol (1,4-BD) results from its presumed conversion to gamma-hydroxybutyrate (GHB) and subsequent pharmacological effects via action on GABA-B and GHB-specific receptors. Using in vivo microdialysis we measured the appearance of GHB in the striata of rats after peripheral 1,4-BD administration. We developed and utilized an HPLC-UV (215 nm) detection of GHB that yielded a limit of quantification (S/N = 10) of 2.0 μg/mL (40 ng/injection) and a limit of detection (S/N = 3) of 0.75 μg/mL (15 ng/injection). GHB appeared in the striatal microdialysates within 20 min after intraperitoneal (i.p.) administration of varying doses of 1,4-BD. GHB concentrations reached dose-dependent maxima 80–100 min post-1,4-BD administration, with peak values of 10.6 ± 2.9, 25.3 ± 3.4 and 48.1 ± 7.1 μg/mL (mean ± S.E.M.), corresponding to 1,4-BD doses of 250, 500 and 750 mg/kg, respectively. The conversion of 1,4-BD to GHB was completely prevented by the alcohol dehydrogenase inhibitor 4-methylpyrazole (4MP), administered prior to 1,4-BD, as evidenced by the failure of GHB to appear in the striatal microdialysates. Sleep times in animals were similarly correlated with GHB concentrations in the microdialysates.

Related Topics

    loading  Loading Related Articles